FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

In our exclusive interview, Dr Bardia discussed the significance of this approval, pivotal findings from the phase 3 TROPION-Breast01 trial (NCT05104866), the clinical relevance of being able to improve progression-free survival and quality of life with Dato-DXd compared with standard chemotherapy, and key considerations for sequencing antibody-drug conjugates.